anacardic acid has been researched along with Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balzano, AL; Castellano, S; Feoli, A; La Pietra, V; Mai, A; Marinelli, L; Milite, C; Novellino, E; Sasaki, K; Sbardella, G; Tosco, A | 1 |
| Chen, K; Chen, Y; Chen, Z; Ding, H; Han, J; Jiang, H; Liu, YC; Lu, T; Lu, W; Luo, C; Wang, C; Wang, J; Xiao, S; Xiong, H; Xu, P; Yang, Y; Yue, L; Zhang, C; Zhang, H; Zhang, Y; Zhou, B | 1 |
2 other study(ies) available for anacardic acid and Leukemia
| Article | Year |
|---|---|
A novel cell-permeable, selective, and noncompetitive inhibitor of KAT3 histone acetyltransferases from a combined molecular pruning/classical isosterism approach.
Topics: Acetylation; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Histones; Humans; Leukemia; Lysine; Models, Molecular; p300-CBP Transcription Factors | 2015 |
Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Discovery; Enzyme Inhibitors; Female; Humans; Leukemia; Mice, Nude; Molecular Docking Simulation; p300-CBP Transcription Factors; Thiobarbiturates; Transcriptome | 2018 |